Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Systematic Biopsy Does Not Contribute to Disease Upgrading in Patients Undergoing Targeted Biopsy for PI-RADS 5 Lesions Identified on Magnetic Resonance Imaging in the Course of Active Surveillance for Prostate Cancer.

Arabi A, Deebajah M, Yaguchi G, Pantelic M, Williamson S, Gupta N, Park H, Peabody J, Menon M, Dabaja A, Alanee S.

Urology. 2019 Aug 31. pii: S0090-4295(19)30789-7. doi: 10.1016/j.urology.2019.08.035. [Epub ahead of print]

PMID:
31479660
2.

Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior Biopsies.

Preisser F, Theissen L, Wenzel M, Humke C, Bodelle B, Köllermann J, Kluth L, Banek S, Becker A, Roos F, Chun FK, Mandel P.

Eur Urol Focus. 2019 Jul 8. pii: S2405-4569(19)30170-1. doi: 10.1016/j.euf.2019.06.015. [Epub ahead of print]

PMID:
31296485
3.

A prospective study of magnetic resonance imaging and ultrasonography (MRI/US)-fusion targeted biopsy and concurrent systematic transperineal biopsy with the average of 18-cores to detect clinically significant prostate cancer.

Hakozaki Y, Matsushima H, Kumagai J, Murata T, Masuda T, Hirai Y, Oda M, Kawauchi N, Yokoyama M, Homma Y.

BMC Urol. 2017 Dec 12;17(1):117. doi: 10.1186/s12894-017-0310-7.

4.

Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.

Cash H, Günzel K, Maxeiner A, Stephan C, Fischer T, Durmus T, Miller K, Asbach P, Haas M, Kempkensteffen C.

BJU Int. 2016 Jul;118(1):35-43. doi: 10.1111/bju.13327. Epub 2015 Oct 20.

5.

Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?

Exterkate L, Wegelin O, Barentsz JO, van der Leest MG, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, van Melick HHE, Somford DM.

Eur Urol Oncol. 2019 Jun 22. pii: S2588-9311(19)30080-X. doi: 10.1016/j.euo.2019.06.005. [Epub ahead of print]

PMID:
31239236
6.

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease.

Schoots IG, Osses DF, Drost FH, Verbeek JFM, Remmers S, van Leenders GJLH, Bangma CH, Roobol MJ.

Transl Androl Urol. 2018 Feb;7(1):132-144. doi: 10.21037/tau.2017.12.29.

7.

Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.

Maxeiner A, Kittner B, Blobel C, Wiemer L, Hofbauer SL, Fischer T, Asbach P, Haas M, Penzkofer T, Fuller F, Miller K, Cash H.

BJU Int. 2018 Aug;122(2):211-218. doi: 10.1111/bju.14212. Epub 2018 Apr 17.

8.

The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.

Ma TM, Tosoian JJ, Schaeffer EM, Landis P, Wolf S, Macura KJ, Epstein JI, Mamawala M, Carter HB.

Eur Urol. 2017 Feb;71(2):174-180. doi: 10.1016/j.eururo.2016.05.021. Epub 2016 May 25.

PMID:
27236496
9.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

10.

Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B.

BJU Int. 2017 Nov;120(5):631-638. doi: 10.1111/bju.13711. Epub 2016 Dec 21.

11.
12.

PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.

Zhai L, Fan Y, Sun S, Wang H, Meng Y, Hu S, Wang X, Yu W, Jin J.

Scand J Urol. 2018 Oct - Dec;52(5-6):333-339. doi: 10.1080/21681805.2018.1545799.

PMID:
30895901
13.

Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.

Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, Bjurlin MA, Marshall S, Deng FM, Zhou M, Melamed J, Huang WC, Lepor H, Taneja SS.

Eur Urol. 2016 Mar;69(3):512-7. doi: 10.1016/j.eururo.2015.06.005. Epub 2015 Jun 22.

14.

Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance.

Radtke JP, Kuru TH, Bonekamp D, Freitag MT, Wolf MB, Alt CD, Hatiboglu G, Boxler S, Pahernik S, Roth W, Roethke MC, Schlemmer HP, Hohenfellner M, Hadaschik BA.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):283-91. doi: 10.1038/pcan.2016.16. Epub 2016 May 17.

PMID:
27184812
15.

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.

Venderink W, van Luijtelaar A, Bomers JG, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, Sedelaar JP, Fütterer JJ.

Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110-0. doi: 10.1016/j.eururo.2017.02.021. [Epub ahead of print]

PMID:
28258784
16.

Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.

Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O'Sullivan R, Distler F, Warren A, Samel C, Hadaschik B, Grummet J, Kastner C.

BJU Int. 2018 Jul;122(1):40-49. doi: 10.1111/bju.14049. Epub 2017 Nov 15.

17.

The addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsy.

Günzel K, Cash H, Buckendahl J, Königbauer M, Asbach P, Haas M, Neymeyer J, Hinz S, Miller K, Kempkensteffen C.

BMC Urol. 2017 Jan 13;17(1):7. doi: 10.1186/s12894-016-0196-9.

18.

Accuracy of Sampling PI-RADS 4-5 Index Lesions Alone by MRI-guided In-bore Biopsy in Biopsy-naive Patients Undergoing Radical Prostatectomy.

Kılıc M, Vural M, Coskun B, Acar Ö, Saglican Y, Akpek S, Esen T.

Eur Urol Focus. 2019 May 2. pii: S2405-4569(19)30126-9. doi: 10.1016/j.euf.2019.04.010. [Epub ahead of print]

PMID:
31054811
19.

The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.

Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, Asbach P, Haas M, Hinz S, Neymeyer J, Miller K, Günzel K, Kempkensteffen C.

World J Urol. 2016 Apr;34(4):525-32. doi: 10.1007/s00345-015-1671-8. Epub 2015 Aug 21.

PMID:
26293117
20.

MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?

Rührup J, Preisser F, Theißen L, Wenzel M, Roos FC, Becker A, Kluth LA, Bodelle B, Köllermann J, Chun FKH, Mandel P.

Front Surg. 2019 Sep 18;6:55. doi: 10.3389/fsurg.2019.00055. eCollection 2019.

Supplemental Content

Support Center